Target intelligence / Profile preview

Mycotoxin

Molecular classification
Other (toxic fungal metabolites)
01

Overview

Mycotoxins are chemically diverse toxic secondary metabolites produced by filamentous fungi such as Aspergillus, Fusarium, Penicillium, and Claviceps[1][3][5][7]. Hundreds of types exist, but a small subset cause the greatest risk to human and animal health, notably aflatoxins, ochratoxin A, fumonisins, zearalenone, and deoxynivalenol[1][3][5][9]. These compounds can contaminate crops and foodstuffs, especially under warm, humid conditions, and are chemically stable, often surviving food processing[9]. Their biological effects vary: aflatoxins are strongly carcinogenic and hepatotoxic; ochratoxin A is nephrotoxic and carcinogenic; deoxynivalenol is immunosuppressive and causes protein synthesis inhibition[6]. Mycotoxins do not serve as druggable targets in the sense of traditional pharmacology; rather, they are hazardous environmental agents, and research is focused on detection, detoxification, and mitigation of their effects on health[1][10]. In summary, mycotoxins refer to a broad chemical class of toxic fungal metabolites, not an individual target molecule or protein. Therefore, most fields above are either inapplicable or reflect the broad toxicological relevance, not target-drug interaction.

Other names
Mycotoxinsfungal toxinssecondary fungal metabolites
02

Mechanism of action

mycotoxins act via direct toxicity, not as a modulated pathway; some cause DNA adduction, inhibition of protein synthesis, apoptosis induction, endocrine disruption, ROS generation, ribotoxic stress

03

Biological functions

Other (not a functional biological molecule; toxic effect includes carcinogenicity, genotoxicity, teratogenicity, immunotoxicity, hepatotoxicity, nephrotoxicity, neurotoxicity, hormone disruption)
04

Disease associations

CancerInfectionImmune deficiencyLiver diseaseNephropathyReproductive disordersGrowth retardation
05

Safety considerations

High carcinogenic and mutagenic potential (especially aflatoxins, linked to liver cancer in humans)immunosuppressionreproductive toxicityacute poisoning riskpersistence in food supply due to chemical stability
06

Interacting drugs

activated carbon

1 more in the full profile.

07

Biomarkers

Certain microRNAs (miRNAs) are being investigated as biomarkers for mycotoxin exposure and toxicity; for example, upregulation of cytokines and specific miRNA profiles may indicate exposure to aflatoxins or deoxynivalenolDecreased IGF1/IGFALS and increased DON levels in urine are considered potential biomarkers for DON (deoxynivalenol) exposure

Beyond the preview

Go deeper on Mycotoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycotoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call